NICE rethinks drugs decision

Almost a year after the controversial launch of its consultation on the withdrawal of four major Alzheimer’s drugs the National Institute for Clinical Excellence (NICE) has issued a draft decision which would see use of three of the treatments maintained for ‘moderate to severe’ sufferers. Under the new guidance, which is open to consultation until…